{"entity":{"id":"nct06697197","kind":"trial","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Nivolumab and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","summary":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06697197 by Bristol-Myers Squibb, with 413 participants planned, started 2025-02-17 and due to reach its primary completion in 2029-01-04. Interventions recorded: BMS-986482, Nivolumab and rHuPH20, Nivolumab/relatlimab/rHuPH20 and Bevacizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06697197","url":"https://clinicaltrials.gov/study/NCT06697197"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","bevacizumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06697197","phase":"1/2","setting":"A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","enrolled":413,"outcomes":[]},"route":"/trials/nct06697197/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}